Yumanity Therapeutics is a biopharmaceutical company focused on the discovery and development of therapies for neurodegenerative diseases. Co.'s primary program, YTX-7739, is in Phase 1 clinical trials for the treatment and disease modification of Parkinson's disease. YTX-7739 targets an enzyme known as stearoyl-CoA desaturase, or SCD. Co. has completed a Phase 1 study of YTX-7739 in healthy volunteers, which evaluated a range of doses of YTX-7739. Co.'s second program, YTX-9184, also inhibits SCD. Co. is developing YTX-9184 for the treatment of dementia with Lewy bodies, which is a neurodegenerative disease characterized by the abnormal accumulation of aggregates of a-synuclein. The YMTX stock yearly return is shown above.
The yearly return on the YMTX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the YMTX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|